Shaun Jayakar, MD
Geriatric Medicine · Warren, MINPI 1770747594
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 9.5% — the pattern of someone who eats at a lot of different presentations.
Across 98 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$175
- GSK$155
- AbbVie$152
- AstraZeneca$145
- Exact Sciences$137
- Novo Nordisk$120
- plus $958 from 22 others
What the payments were for
- Food & beverage$1,74295%
- Education$1005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 4 | $175 |
| GSK | 10 | $155 |
| AbbVie | 7 | $152 |
| AstraZeneca | 10 | $145 |
| Exact Sciences | 8 | $137 |
| Novo Nordisk | 6 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $115 |
| Abbott | 6 | $106 |
| Pfizer | 5 | $98 |
| Dexcom, Inc. | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 5 | $86 |
| Harmony Biosciences LLC | 3 | $77 |
| Lilly USA, LLC | 4 | $65 |
| Corcept Therapeutics | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Shield Therapeutics Inc | 1 | $22 |
| Amgen | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Abiomed | 1 | $14 |
How this compares
$1,842 in reported general payments places this provider in the 85th percentile of 168 geriatric medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 160 | $181,978 |
| EliquisApixaban | 116 | $89,432 |
| OzempicSemaglutide | 60 | $59,431 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $54,294 |
| TradjentaLinagliptin | 78 | $42,065 |
| XareltoRivaroxaban | 39 | $30,009 |
| JardianceEmpagliflozin | 30 | $23,728 |
| EntrestoSacubitril/Valsartan | 25 | $19,108 |
| LinzessLinaclotide | 13 | $17,507 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $15,331 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $14,660 |
| FarxigaDapagliflozin Propanediol | 23 | $13,265 |
| Diclofenac Sodium | 117 | $11,259 |
| Metformin Hcl | 329 | $9,632 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $65 | $181,978160 claims |
| PfizerEliquis | $98 | $89,432116 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $155 | $63,67683 claims |
| Novo NordiskOzempic | $120 | $59,43160 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta | $145 | $32,59756 claims |
| Johnson & JohnsonXarelto | $14 | $30,00939 claims |
| AbbVieLinzess | $152 | $17,50713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 168 geriatric medicine providers in Michigan.
Other geriatric medicine in Warren
- Gerald DaneshvarHamtramck$23K
- Jailan ElayoubiDearborn$20K
- Grace JenqAnn Arbor$12K
- Afriyie GrayGrand Rapids$12K
- Bnan RazokyTroy$11K
- Saket SaxenaDetroit$11K
- Randolph SchumacherFlint$9K
- Ronald BarnettLivonia$7K
- Michael BurryLivonia$7K
- Keith TobinLivonia$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.